NEP Enzyme Activity Increases in Heart Failure, Potentially Limiting Protective Peptide Effects
In a volume-overload heart failure model, NEP activity is increased alongside elevated natriuretic peptides, suggesting the enzyme limits the protective effects of these cardiac peptides.
Quick Facts
What This Study Found
NEP activity is increased in volume-overload heart failure, potentially accelerating the breakdown of protective natriuretic peptides even as the heart produces more of them.
Key Numbers
How They Did This
Aortovenocaval fistula rat model of heart failure with measurement of NEP activity, natriuretic peptide levels, and renin-angiotensin-aldosterone system activation.
Why This Research Matters
If NEP destroys protective peptides faster in heart failure, inhibiting NEP could restore the balance between vasodilator and vasoconstrictor forces — a key therapeutic principle.
The Bigger Picture
This study revealed a vicious cycle in heart failure where the enzyme that destroys protective peptides increases alongside the peptides themselves, providing further rationale for NEP inhibitor therapy.
What This Study Doesn't Tell Us
Surgical animal model that may not fully represent human chronic heart failure. NEP activity measurement may not reflect tissue-specific activity.
Questions This Raises
- ?Does NEP inhibition restore natriuretic peptide levels in heart failure?
- ?Is increased NEP activity a cause or consequence of heart failure progression?
Trust & Context
- Key Stat:
- NEP increases in heart failure NEP activity rose alongside natriuretic peptides, suggesting it limits their protective effects in a vicious cycle
- Evidence Grade:
- Moderate animal evidence from a well-established heart failure model. Provides pathophysiological insight supporting NEP inhibitor therapy.
- Study Age:
- Published in 1996, contributing to the growing evidence that led to sacubitril development for heart failure.
- Original Title:
- Role of neutral endopeptidase 24.11 in AV fistular rat model of heart failure.
- Published In:
- Cardiovascular research, 31(6), 891-8 (1996)
- Authors:
- Wegner, M(2), Hirth-Dietrich, C, Stasch, J P(2)
- Database ID:
- RPEP-00393
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
What happens to natriuretic peptides in heart failure?
The heart produces more ANP and BNP as it struggles, trying to lower blood pressure and reduce fluid overload. But this study shows the enzyme that destroys them (NEP) also increases, creating a futile cycle where the body can't get enough benefit from its own protective peptides.
How does this explain why Entresto works?
By blocking NEP, sacubitril (in Entresto) stops the enzyme from destroying natriuretic peptides. In heart failure, where NEP activity is already elevated, this intervention restores the protective peptide effects the heart is desperately trying to achieve.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00393APA
Wegner, M; Hirth-Dietrich, C; Stasch, J P. (1996). Role of neutral endopeptidase 24.11 in AV fistular rat model of heart failure.. Cardiovascular research, 31(6), 891-8.
MLA
Wegner, M, et al. "Role of neutral endopeptidase 24.11 in AV fistular rat model of heart failure.." Cardiovascular research, 1996.
RethinkPeptides
RethinkPeptides Research Database. "Role of neutral endopeptidase 24.11 in AV fistular rat model..." RPEP-00393. Retrieved from https://rethinkpeptides.com/research/wegner-1996-role-of-neutral-endopeptidase
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.